Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ELOVL2 is a novel tumor suppressor attenuating tamoxifen resistance in breast cancer via suppressing the AKT pathway [methylation 850K]

ABSTRACT: Genome wide DNA methylation profiling of tamoxifen-resistant(Tam-R) breast cancer cell line MCF-7. The Illumina Infinium MethylationEPIC BeadChip was used to obtain DNA methylation profiles across approximately 850,000 CpGs.

ORGANISM(S): Homo sapiens

PROVIDER: GSE132616 | GEO | 2020/06/12

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Shared Molecules

Only show the datasets with similarity scores above: 0.5

Threshold

0.5

Similar Datasets

ELOVL2 is a novel tumor suppressor attenuating tamoxifen resistance in breast cancer via suppressing the AKT pathway [methylation 450K]

Project description:Genome wide DNA methylation profiling of tamoxifen-resistant(Tam-R) breast cancer cell line MCF-7. The Illumina Infinium Human Methylation 450k Bead chip was used to obtain DNA methylation profiles across approximately 450,000 CpGs.

2020-06-12 | GSE132615 | GEO

ELOVL2 is a novel tumor suppressor attenuating tamoxifen resistance in breast cancer via suppressing the AKT pathway

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-06-12 | GSE132617 | GEO

ELOVL2 is a novel tumor suppressor attenuating tamoxifen resistance in breast cancer via suppressing the AKT pathway [gene expression]

Project description:Analysis of tamoxifen-sensitivity recovery effect by genes which are regulated by ELOVL2(Elongation of very long chain fatty acids protein 2) at gene expression level in breast cancer. This study identifies that ELOVL2 regulates AKT or ER signaling-related genes and ELOVL2 as an essential gene responsible for resistance.

2020-06-12 | GSE132614 | GEO

ELOVL2 is a novel tumor suppressor attenuating tamoxifen resistance in breast cancer via suppressing the AKT pathway [methylation 850K]

Project description:ELOVL2 is a novel tumor suppressor attenuating tamoxifen resistance in breast cancer via suppressing the AKT pathway [methylation 850K]

| PRJNA548634 | ENA

ELOVL2: a novel tumor suppressor attenuating tamoxifen resistance in breast cancer.

Project description:Epigenetic events have successfully explained the cause of various cancer types, but little is known about tamoxifen resistance (TamR) that induces cancer recurrence. In this study, via genome-wide methylation analysis in MCF-7/TamR cells we show that elongation of very-long chain fatty acid protein 2 (ELOVL2) was hypermethylated and downregulated in the samples from TamR breast cancer patients (n = 28) compared with those from Tam-sensitive (TamS) patients (n = 33) (P < 0.001). Strikingly, in addition to having tumor suppressor activity, ELOVL2 was shown to recover Tam sensitivity up to 70% in the MCF-7/TamR cells and in a xenograft mouse model. A group of genes in the AKT and ERa signaling pathways, e.g., THEM4, which play crucial roles in drug resistance, were found to be regulated by ELOVL2. This study implies that the deregulation of a gene in fatty acid metabolism can lead to drug resistance, giving insight into the development of a new therapeutic strategy for drug-resistant breast cancer.

| S-EPMC8263635 | biostudies-literature

ELOVL2 is a novel tumor suppressor attenuating tamoxifen resistance in breast cancer via suppressing the AKT pathway [methylation 450K]

Project description:ELOVL2 is a novel tumor suppressor attenuating tamoxifen resistance in breast cancer via suppressing the AKT pathway [methylation 450K]

| PRJNA548633 | ENA

Whole transcriptome and 850k methylome profiling of human MBM

Project description:Assessment of methylation status of ~850,000 sites

| EGAD00010002281 | EGA

Methylation profiling of the aging epidermis [850k]

Project description:DNA methylation array data generated from epidermal samples (suction blister roofs) of healthy female subjects between 21 and 76 years. Aim of the project was the investigation of non-linearities in the human aging progression using an integrative multi-omics analysis. DNA was extracted from suction blisters taken from the volar forearms of each subject, bisulfite converted, and profiled using Illumina Infinium MethylationEPIC BeadChip arrrays.

2020-07-24 | E-MTAB-8993 | biostudies-arrayexpress

ELOVL2 is a novel tumor suppressor attenuating tamoxifen resistance in breast cancer via suppressing the AKT pathway

Project description:ELOVL2 is a novel tumor suppressor attenuating tamoxifen resistance in breast cancer via suppressing the AKT pathway

| PRJNA548537 | ENA

Genome wide methylation analysis of 16 melanoma cell lines

Project description:Genome wide DNA methylation profiling of sixteen melanoma cell lines. The Illumina Infinium MethylationEPIC DNA methylation Beadchip was used to obtain DNA methylation profiles across approximately 850,000 CpGs from the cell lines at baseline.

2018-08-31 | GSE114721 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data